Clinical Trials

A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination with Anti-cancer Agents in Patients with

ClinicalTrials.gov Identifier

NCT05417594

Principal Investigator

Andrew Brenner, MD, PhD

For more information about this study
View Details

About This Study

This is a first time in human study primarily designed to evaluate the safety and tolerability of AZD9574 as monotherapy and in combination with anti-cancer agents at increasing dose levels in participants with advanced solid malignancies.